Neuland Labs.

Who are the top shareholders of the Neuland Labs.?

The top shareholders of Neuland Labs include the Davuluri Ownership Trust with 25.98%, individual investors with 25.86%, and 189 Foreign Institutional Investors holding 22.11%. The highest public shareholder is Malabar India Fund Limited at 5.76%, with no pledged promoter holdings reported.

The top shareholders of Neuland Labs include the Davuluri Ownership Trust, which holds the largest stake at 25.98%. Additionally, individual investors collectively own 25.86% of the company. Among institutional investors, 189 Foreign Institutional Investors (FIIs) hold 22.11%, while mutual funds are represented by 23 schemes with a combined holding of 7.43%. The highest public shareholder is Malabar India Fund Limited, with a stake of 5.76%. There are no pledged promoter holdings reported.

how big is Neuland Labs.?

As of Jun 06, Neuland Laboratories Ltd has a market capitalization of 16,789.83 Cr, with recent net sales of 1,476.83 Cr and net profit of 260.11 Cr over the last four quarters. Shareholder's funds are 1,282.70 Cr, and total assets are valued at 1,832.56 Cr as of Mar'24.

Market Cap: As of Jun 06, Neuland Laboratories Ltd has a market capitalization of 16,789.83 Cr, classifying it as a Mid Cap company.<BR><BR>Recent Quarterly Performance: For the latest four quarters, the sum of Net Sales is 1,476.83 Cr and the sum of Net Profit is 260.11 Cr. This data is Consolidated.<BR><BR>Balance Sheet Snapshot: This is Consolidated data for the latest annual period ending in Mar'24. The Shareholder's Funds amount to 1,282.70 Cr, and the Total Assets are valued at 1,832.56 Cr.

When is the next results date for Neuland Labs.?

No Upcoming Board Meetings

Who are in the management team of Neuland Labs.?

As of March 2023, the management team of Neuland Labs includes D R Rao (Executive Chairman), D Sucheth Rao (Vice Chairman & CEO), D Saharsh Rao (Vice Chairman & Managing Director), and Sarada Bhamidipati (Company Secretary & Compliance Officer), along with several independent directors. This team is responsible for the company's governance and strategic direction.

As of March 2023, the management team of Neuland Labs includes the following individuals:<BR><BR>1. D R Rao - Executive Chairman<BR>2. D Sucheth Rao - Vice Chairman & CEO<BR>3. D Saharsh Rao - Vice Chairman & Managing Director<BR>4. Sarada Bhamidipati - Company Secretary & Compliance Officer<BR><BR>Additionally, the board of directors features several independent directors, including:<BR>- H Dhanrajgir<BR>- P V Maiya<BR>- Christopher M Cimarusti<BR>- Bharati Rao<BR>- Nirmala Murthy<BR>- Homi Rustam Khusrokhan<BR>- Prasad R Menon<BR>- Sugata Sircar<BR>- Pallavi Joshi Bakhru<BR><BR>This team plays a crucial role in the governance and strategic direction of the company.

What does Neuland Labs. do?

Neuland Laboratories Ltd manufactures and sells bulk drugs in the Pharmaceuticals & Biotechnology industry, with a market cap of Rs 16,721 Cr. As of March 2025, it reported net sales of 328 Cr and a net profit of 28 Cr.

Overview:<BR>Neuland Laboratories Ltd is engaged in the manufacturing and selling of bulk drugs within the Pharmaceuticals & Biotechnology industry and operates as a mid-cap company.<BR><BR>History:<BR>Incorporated on January 7, 1984, Neuland Laboratories Limited was promoted by Davuluri Sucheth Rao. The company merged with Neuland Drugs & Pharmaceuticals Pvt. Ltd. in April 1992. The latest quarterly results reported net sales and net profit for the period ending March 2025.<BR><BR>Financial Snapshot:<BR>Net Sales: 328 Cr (Quarterly Results - Mar 2025) <BR>Net Profit: 28 Cr (Quarterly Results - Mar 2025) <BR>Market Cap: Rs 16,721 Cr (Mid Cap)<BR><BR>Key Metrics:<BR>P/E: 76.00 <BR>Industry P/E: 35 <BR>Dividend Yield: 0.12% <BR>Debt-Equity: -0.14 <BR>Return on Equity: 13.13% <BR>Price to Book: 9.93 <BR><BR>Contact Details:<BR>Address: 11 Th Floor Phoenix IVY Buildi, Plot No 573A-III Road No 82 Hyderabad Telangana : 500035 <BR>Tel: 91-40-30211600 <BR>Email: ir@neulandlabs.com <BR>Website: http://www.neulandlabs.com

Has Neuland Labs. declared dividend?

Yes, Neuland Laboratories Ltd has declared a dividend of 140% (₹14 per share) with an ex-date of July 12, 2024. While recent returns have been volatile, the company has shown substantial long-term growth, with a total return of 3148.39% over the past five years.

Neuland Laboratories Ltd has declared a dividend.<BR><BR>Dividend Details:<BR>- Percentage announced: 140%<BR>- Amount per share: 14<BR>- Ex-date: 12 Jul 24<BR><BR>Dividend Yield: 0.12%.<BR><BR>Total Returns by Period:<BR>In the last 6 months, the price return was -25.58%, with a dividend return of 0%, resulting in a total return of -25.58%.<BR><BR>Over the past year, the price return was 112.28%, the dividend return was 0.22%, leading to a total return of 112.5%.<BR><BR>In the 2-year period, the price return was 347.43%, with a dividend return of 0.82%, culminating in a total return of 348.25%.<BR><BR>For the 3-year period, the price return was 1133.21%, the dividend return was 2.76%, resulting in a total return of 1135.97%.<BR><BR>In the last 4 years, the price return was 522.76%, with a dividend return of 1.61%, leading to a total return of 524.37%.<BR><BR>Over the past 5 years, the price return was 3142.13%, with a dividend return of 6.26%, resulting in a total return of 3148.39%.<BR><BR>Overall, Neuland Laboratories Ltd has declared a significant dividend, and while the recent returns have shown volatility, particularly in the short term, the longer-term performance indicates substantial growth in total returns, driven largely by price appreciation.

Who are the peers of the Neuland Labs.?

Neuland Labs. peers include Sun Pharma, Divi's Lab, Cipla, Torrent Pharma, Dr Reddy's Labs, Sanofi India, Alivus Life, Granules India, and Marksans Pharma. Neuland Labs. has average management risk and growth, with a 1-year return of 92.19%, while peers show varying management risks and returns.

Peers: The peers of Neuland Labs. are Sun Pharma.Inds., Divi's Lab., Cipla, Torrent Pharma, Dr Reddy's Labs, Sanofi India, Alivus Life, Granules India, Sanofi Consumer, and Marksans Pharma.<BR><BR>Quality Snapshot: Excellent management risk is observed at Sun Pharma.Inds., Cipla, Dr Reddy's Labs, and Sanofi India, while Good management risk is found at Divi's Lab., Torrent Pharma, Alivus Life, Granules India, and Marksans Pharma. Average management risk is noted at Neuland Labs. Growth is Excellent for Sun Pharma.Inds., Cipla, and Dr Reddy's Labs, while Average growth is seen at Neuland Labs. Below Average growth is reported for Divi's Lab., Torrent Pharma, Sanofi India, Alivus Life, Granules India, and Marksans Pharma. Excellent capital structure is present at Sun Pharma.Inds., Divi's Lab., Cipla, Dr Reddy's Labs, Neuland Labs., Sanofi India, Alivus Life, Granules India, and Marksans Pharma, while Good capital structure is noted at Torrent Pharma.<BR><BR>Return Snapshot: Divi's Lab. has the highest 1-year return at 51.69%, while Sanofi India has the lowest at -29.01%. Neuland Labs. has a 1-year return of 92.19%, which is significantly higher than Sanofi India's. Additionally, the peers with negative six-month returns include Neuland Labs., Sanofi India, and Marksans Pharma.

Is Neuland Labs. overvalued or undervalued?

As of November 8, 2023, Neuland Labs is considered very expensive with a PE ratio of 83.55, significantly higher than its peers, indicating potential overvaluation despite a strong 1-year stock return of 105.28%.

As of 8 November 2023, Neuland Labs' valuation grade has moved from expensive to very expensive, indicating a significant increase in perceived overvaluation. The company is currently assessed as overvalued, with a PE ratio of 83.55, a Price to Book Value of 10.97, and an EV to EBITDA ratio of 51.10. These metrics suggest that the stock is trading at a premium compared to its earnings and book value.<BR><BR>In comparison to its peers, Neuland Labs stands out with a notably higher PE ratio than Sun Pharma, which has a PE of 35.25, and Divi's Lab at 79.33. Other peers like Cipla and Dr. Reddy's Labs exhibit much lower valuations, with PE ratios of 22.99 and 19.49, respectively. Despite recent strong stock performance, with a 1-year return of 105.28% compared to the Sensex's 7.58%, the elevated valuation metrics indicate that Neuland Labs may not sustain its current price levels in the long term.

Is Neuland Labs. technically bullish or bearish?

As of October 8, 2025, the trend has shifted to bullish with strong indicators like the weekly MACD and Bollinger Bands supporting this view, although caution is advised due to mildly bearish monthly MACD and KST signals.

As of 8 October 2025, the technical trend has changed from mildly bullish to bullish. The current stance is bullish with strong indicators supporting this view. The weekly MACD is bullish, and both the weekly and monthly Bollinger Bands are bullish. Daily moving averages also confirm a bullish trend. However, the monthly MACD and KST are mildly bearish, indicating some caution. Overall, the strength of the bullish trend is reinforced by the positive returns over various periods, particularly the impressive 3-year and 5-year returns compared to the Sensex.

How has been the historical performance of Neuland Labs.?

Neuland Labs experienced fluctuating financial performance, with net sales and operating income peaking at 1,558.58 Cr in March 2024 before declining to 1,476.84 Cr in March 2025, while profit metrics also decreased. However, total assets and cash flow from operating activities improved during the same period.

Answer:<BR>The historical performance of Neuland Labs shows a fluctuating trend in key financial metrics over the years.<BR><BR>Breakdown:<BR>Neuland Labs' net sales peaked at 1,558.58 Cr in March 2024 but declined to 1,476.84 Cr by March 2025. The total operating income followed a similar pattern, reaching 1,558.58 Cr in March 2024 before dropping to 1,476.84 Cr in March 2025. Raw material costs increased from 360.44 Cr in March 2019 to 574.81 Cr in March 2025, while employee costs rose from 110.46 Cr in March 2019 to 272.00 Cr in March 2025. Operating profit (PBDIT) saw a decline from 475.13 Cr in March 2024 to 343.78 Cr in March 2025, with a corresponding decrease in profit before tax from 401.44 Cr to 346.33 Cr. Profit after tax also fell from 300.08 Cr in March 2024 to 260.11 Cr in March 2025. The company's total assets increased significantly from 1,230.98 Cr in March 2020 to 2,179.88 Cr in March 2025, while total liabilities rose from 1,230.98 Cr to 2,179.88 Cr in the same period. Cash flow from operating activities improved from 261.00 Cr in March 2024 to 317.00 Cr in March 2025, contributing to a net cash inflow of 44.00 Cr by March 2025.

Should I buy, sell or hold Neuland Laboratories Ltd?

Why is Neuland Laboratories Ltd falling/rising?

As of 12-May, Neuland Laboratories Ltd's stock price is falling, currently at 17,000.55, reflecting a decrease of 3.12%. Recent declines, underperformance against its sector, and concerns about long-term growth prospects are contributing to this downward trend.

As of 12-May, Neuland Laboratories Ltd's stock price is falling, currently at 17,000.55, reflecting a decrease of 547.75 or 3.12%. This decline is part of a broader trend, as the stock has been losing value for the last two days, resulting in a total drop of 3.25% during this period. Additionally, the stock underperformed its sector by 0.96% today.<BR><BR>Despite its strong performance over longer periods, such as a 35.30% return over the past year and a remarkable 558.83% increase over the last three years, the recent price movement indicates some negative sentiment. The stock reached an intraday low of Rs 16,912.25, which is a 3.62% decrease from its previous price. <BR><BR>Moreover, while there has been rising investor participation, with delivery volume increasing by 47.96% against the 5-day average, the overall market conditions are not favorable, as evidenced by the Sensex's decline of 3.19% over the past week. The company's recent financial results, although positive with a 424.21% growth in net profit, have not been enough to offset the concerns regarding poor long-term growth, as net sales have only grown at an annual rate of 12.25% over the last five years. <BR><BR>In summary, the combination of recent price declines, underperformance relative to the sector, and concerns about long-term growth prospects are contributing to the falling stock price of Neuland Laboratories Ltd.

Which are the latest news on Neuland Labs.?

Are Neuland Laboratories Ltd latest results good or bad?

Neuland Laboratories Ltd's latest Q4 FY26 results are impressive, with a net profit increase of 424.21% quarter-on-quarter and 664.72% year-on-year, alongside significant revenue growth. However, the annual results show a decline in revenue and profit, indicating potential challenges in sustaining this strong performance.

Neuland Laboratories Ltd's latest results for Q4 FY26 are quite impressive. The company reported a net profit of ₹212.67 crores, which marks a staggering increase of 424.21% quarter-on-quarter and 664.72% year-on-year. Additionally, revenue surged to ₹776.25 crores, reflecting a growth of 76.54% from the previous quarter and 136.40% compared to the same quarter last year. <BR><BR>The operating margin, excluding other income, improved significantly to 39.59%, up from 17.54% in the prior quarter, indicating strong operational efficiency. The profit after tax margin also rose to 27.40%, showcasing the company's ability to convert revenue growth into substantial profit.<BR><BR>However, while the quarterly performance is exceptional, the annual results present a more mixed picture. For the full year FY25, Neuland Laboratories experienced a decline in revenue by 5.3% and a 13.33% drop in net profit compared to FY24. This suggests that while the recent quarter was outstanding, there are underlying challenges in sustaining such performance consistently.<BR><BR>Overall, the latest quarterly results are certainly good, demonstrating a strong turnaround and operational strength, but the annual decline raises questions about the sustainability of this performance moving forward.